Efficacy of a dose range of surinabant, a cannabinoid receptor blocker, for smoking cessation: a randomized controlled clinical trial

  title={Efficacy of a dose range of surinabant, a cannabinoid receptor blocker, for smoking cessation: a randomized controlled clinical trial},
  author={Serena Tonstad and Henri-Jean Aubin},
  journal={Journal of Psychopharmacology},
  pages={1003 - 1009}
  • S. Tonstad, H. Aubin
  • Published 4 January 2012
  • Medicine, Psychology
  • Journal of Psychopharmacology
A hyperactive endocannabinoid signalling system may contribute to addictions. We tested the efficacy and safety of surinabant, a novel selective CB1 cannabinoid receptor antagonist, for smoking cessation. In a randomized, double-blind, placebo-controlled, parallel-group clinical trial, participants were assigned to brief counselling and one of three doses of surinabant, 2.5 mg/day (n = 199), 5 mg/day (n = 204), or 10 mg/day (n = 205) or placebo (n = 202) orally for 8 weeks with 6 weeks of non… 

Tables from this paper

Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.
The dose-related inhibition by surinabant of CNS effects and heart rate induced by Δ(9) -tetrahydrocannabinol (THC) in humans suggests that this compound behaves as a CB1 receptor antagonist in humans at these concentrations.
Pooled analysis of three randomized, double‐blind, placebo controlled trials with rimonabant for smoking cessation
Rimonabant 20 mg resulted in significantly higher abstinence at end‐of‐treatment and at 48 weeks post‐targeted quit date compared with placebo, while rimonabant 5 mg and placebo did not differ.
Novel approaches in clinical development of cannabinoid drugs
By systematically investigating, it is found that the new cannabinoid antagonist TN38837 seems effective with a reduced propensity for central side effects, and that a new oral THC formulation enhances the pharmacological activities by its seemingly superior pharmacokinetics.
Randomized Clinical Trials Investigating Innovative Interventions for Smoking Cessation in the Last Decade.
Clinical trials published within the past 10 years investigating novel smoking cessation pharmacotherapies showed promising results, such as cytisine and endocannabinoid modulators, whereas others failed to produce significant effects.
Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions.
  • D. Harmey, P. Griffin, P. Kenny
  • Biology, Medicine
    Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
  • 2012
Current clinical assessment of potential smoking cessation agents offers the promise of new effective medications, and many examples of novel small molecule drug development around non-nAChR targets are highlighted.
Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease: A Network Meta-Analysis of Randomized Controlled Trials
Varenicline and bupropion, as well as individual and telephone counseling, are efficacious for smoking cessation in CVD patients, according to a meta-analysis of randomized controlled trials.
Emerging drugs for the treatment of tobacco dependence: 2014 update
Current evidence suggests that the two most effective pharmacotherapies to treat tobacco dependence are varenicline and combination nicotine replacement therapy, both of which demonstrate mixed rates of success in achieving long-term abstinence from smoking.
Pharmacokinetic/pharmaco-dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on Δ(9)-tetrahydrocannabinol challenge tests.
AIM The severe psychiatric side effects of cannabinoid receptor type 1 (CB1 ) antagonists hampered their wide development but this might be overcome by careful management of drug development with


Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial
Varenicline was significantly more efficacious than placebo for smoking cessation at all time points and significantly more efficient than sustained-release bupropion SR at the end of 12 weeks of drug treatment and at 24 weeks.
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.
Rimonabant 20 mg may moderate weight gain in the long term, and the evidence for rimonabant in maintaining abstinence is inconclusive.
Rimonabant for treating tobacco dependence
Rimonabant, a selective cannabinoid receptor (type 1) blocker, has been shown in some early clinical trials to have some positive effects in increasing abstinence rates of smokers attempting to stop, but the results from these few trials have not been entirely consistent and so its role as an aid to smoking cessation remains to be determined.
Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?
  • S. Doggrell
  • Medicine
    Expert opinion on investigational drugs
  • 2005
In Sardinian alcohol--preferring rats, in the alcohol-naive state, SR-147778 slowed the development of a preference for alcohol, and when alcohol-experienced sP rats are deprived of alcohol for 15 days, there is a large intake of alcohol on reintroduction ofcohol, and this response was almost abolished by treatment with SR- 147778.
Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials
A meta-analysis to compare the treatment effects of 7 approved pharmacologic interventions for smoking cessation found that varenicline was superior to bupropion and all were more efficacious than placebo at promoting smoking abstinence at 6 and 12 months.
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Varenicline displays high α4β2 nAChR affinity and the desired in vivo dopaminergic profile and provides relief from the craving and withdrawal syndrome that accompanies cessation attempts.
How does bupropion work as a smoking cessation aid?
The principal mode of bupropion action is upon the withdrawal symptoms following smoking cessation, and during withdrawal, buPropion may attenuate symptoms by mimicking nicotinic effects on dopamine and noradrenaline.
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Orlistat, sibutramine, and rimonabant modestly reduce weight, have differing effects on cardiovascular risk profiles, and have specific adverse effects.